Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

NCT01822522 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
HIV Infection
Metastatic Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Unresectable Solid Neoplasm

Interventions

DRUG: Cabozantinib S-malate
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)